Misplaced Pages

You can help expand this article with text translated from the corresponding article in French. (November 2024) Click for important translation instructions. View a machine-translated version of the French article. Machine translation, like DeepL or Google Translate, is a useful starting point for translations, but translators must revise errors as necessary and confirm that the translation is accurate, rather than simply copy-pasting machine-translated text into the English Misplaced Pages. Consider adding a topic to this template: there are already 1,674 articles in the main category, and specifying|topic= will aid in categorization. Do not translate text that appears unreliable or low-quality. If possible, verify the text with references provided in the foreign-language article. You must provide copyright attribution in the edit summary accompanying your translation by providing an interlanguage link to the source of your translation. A model attribution edit summary is Content in this edit is translated from the existing French Misplaced Pages article at ]; see its history for attribution. You may also add the template {{Translated|fr|Laboratoires Boiron}} to the talk page. For more guidance, see Misplaced Pages:Translation.

Boiron

Company type	Public
Traded as	Euronext: BOI
Industry	Alternative medicine
Founded	7 June 1932; 92 years ago (1932-06-07)
Founders	Jean Boiron Henri Boiron
Headquarters	Messimy, France
Area served	worldwide
Key people	Valérie Poinsot (CEO)
Revenue	604 million € (2018)
Net income	57.4 million € (2018)
Number of employees	3,723
Website	www.boiron.fr

Boiron (French pronunciation: [bwaʁɔ̃]) is a manufacturer of homeopathic products, headquartered in France and with an operating presence in 59 countries worldwide. It is the largest manufacturer of homeopathic products in the world. In 2004, it had a workforce of 2,779 and turnover of € 313 million. It is a member of the CAC Small stock index.

In June 2005, the firm acquired Dolisos Laboratories, then the world's second largest manufacturer of homeopathic preparations.

Products of Boiron include mono- (Hahnemanian) and poly-preparations, which Boiron refer to as "proprietary drugs".

Homeopathy is a pseudoscience with no evidence of effectiveness for stated claims or plausible mechanism of medicinal effect, and several class action lawsuits have been filed on behalf of consumers claiming that Boiron's homeopathic products, including Children's Coldcalm and Oscillococcinum, are useless and Boiron's marketing of these products is deceptive.

Controversies

Samuele Riva

Samuele Riva, an Italian blogger, wrote an article about the implausibility of homeopathy, including images of Boiron's products. The company sent a letter to the Internet provider of the blog, but the result was a backlash in favor of freedom of speech.

Lawsuits

The non-profit educational organizations Center for Inquiry (CFI) and the associated Committee for Skeptical Inquiry (CSI) have petitioned the U.S. Food and Drug Administration (FDA), criticizing Boiron for misleading labeling and advertising of Oscillococcinum. "One petition complains that Boiron’s packaging for Oscillococcinum lists the alleged active ingredient – duck liver and heart – in Latin only. Another petition complains that Boiron’s web ad for this product implies that it has received FDA approval." Ronald Lindsay, CFI and CSI president and chief executive officer, contends, "If Boiron is going to sell snake oil, the least they can do is use English on their labels.”

A class action against Boiron, filed in 2011 on behalf of "all California residents who purchased Oscillo at any time within the past four years", charged that Boiron "falsely advertises that Oscillo has the ability to cure the flu because it contains an active ingredient it claims is proven to get rid of flu symptoms in 48 hours." The lawsuit also stated that the listed active ingredient in Oscillococcinum (Oscillo) "is actually Muscovy Duck Liver and Heart ... and has no known medicinal quality." A settlement was reached, with Boiron denying any wrongdoing. As part of the settlement, Boiron agreed to make specific changes to its marketing, including adding to their packaging notices like "These ‘Uses’ have not been evaluated by the Food and Drug Administration" and "C, K, CK, and X are homeopathic dilutions."

While the sector is in crisis following the cessation of reimbursement of homeopathic preparations by social security decided by the Minister of Health Agnès Buzyn, the Boiron group announced that its factory at Montrichard, in Loir-et-Cher had failed to find a buyer. Consequently, the site, which employed approximately 80 people, closed on December 31, 2021.

References

1. "La fusion entre Dolisos et Boiron est effective". La Dépêche (in French). 4 July 2005. Retrieved 2017-03-21.
2. Caulfield, Timothy; Debow, Suzanne (2005). "A systematic review of how homeopathy is represented in conventional and CAM peer reviewed journals". BMC Complementary and Alternative Medicine. 5: 12. doi:10.1186/1472-6882-5-12. PMC 1177924. PMID 15955254.
3. "Fun with homeopaths and meta-analyses of homeopathy trials". Science-Based Medicine. 13 October 2008. Retrieved 2019-11-09.
4. Baran GR, Kiana MF, Samuel SP (2014). "Science, Pseudoscience, and Not Science: How do They Differ?". Healthcare and Biomedical Technology in the 21st Century. Springer. pp. 19–57. doi:10.1007/978-1-4614-8541-4_2. ISBN 978-1-4614-8540-7.
5. "Gina Delrosa vs Boiron, Inc" (PDF). Archived from the original (PDF) on 2013-10-19. Retrieved 2011-09-30.
6. Homeopathic Drugmaker Can't Nix Class Action Archived 2011-10-04 at the Wayback Machine
7. Children's Coldcalm Class Action Lawsuit
8. Boiron Oscillococcinum Class Action Lawsuit
9. "Homeopathy, myth and legend" (in Italian): Part 1, Part 2
10. Turone, Fabio (2011), "Homoeopathy multinational Boiron threatens amateur Italian blogger", BMJ, 343 (published August 12, 2011): d5197, doi:10.1136/bmj.d5197, PMID 21840920, S2CID 206893627
11. "Citizen Petition calls on US FDA to review regulation of homeopathic drugs". The Pharma Letter. 18 September 2011. Retrieved 2011-09-20.
12. "Boiron Oscillococcinum Class Action Lawsuit". Top Class Actions. 8 August 2011. Retrieved 2011-09-24.
13. "Gallucci v. Boiron, Inc. et al Settlement Agreement" (PDF). Archived from the original (PDF) on 16 March 2013. Retrieved 30 May 2012.
14. Jordan Pouille (19 January 2021). "A Montrichard, l'usine de Boiron fermera définitivement ses portes le 31 décembre". Le Monde.

External links

• Official Boiron website (in French)
• Official Boiron US website
• Official Boiron India website

• Homeopathic organizations
• Healthcare companies of France
• French brands
• Rhône (department)
• Companies based in Auvergne-Rhône-Alpes
• Companies listed on Euronext Paris
• French companies established in 1932